R&D center
The research direction and strategy is the "Human Network".
The research direction and strategy of the DIOGENE Biomedical Science Laboratory is the "Human Network".
Independent operation of R&D team
The DIOGENE Biomedical Science Laboratory, operated by its own R&D team for each research subject, has launched the cancer genetic testing product "TumorClean™" through constant R&D, and has focused on improving and improving the quality of "BraClean™", a genetic breast cancer genetic mutation analysis reagent. We will also strive to acquire more diverse customers by developing and securing more disease diagnosis reagents.
Diverse service program
Improve and diversify our service programs through mutual collaboration with domestic and foreign hospitals, genomic analysis companies, university research institutes, and government-run laboratories.
BIO network
A close network with overseas research institutions, bio-companies, and scholars to expand services to customers in East Asian countries and overseas countries with relatively similar genetic backgrounds to Koreans.
Research area
The DIOGENE Biomedical Science Laboratory is creating a new paradigm for R&D research in the field of molecular diagnostics.
DIOGENE carries out testing services for infectious diseases, hereditary diseases, chronic diseases and other related diseases using the latest molecular biology diagnostic TOOL.
In addition, we are working with the researchers of the institute to create a new paradigm for R&D in the field of molecular diagnostics through constant efforts to develop new testing methods and diagnostic reagents.
Clinical trial
Target disease | Designation | Source technology research | Candidate material selection | Analytical performance evaluation | Clinical trial |
---|---|---|---|---|---|
Lower urinary tract reproductive disease | DLP™Q STI 12 Real Detection | ||||
Pneumonia | DLP™Q PM8 Real Detection | ||||
Tuberculosis | DLP™Q TB/NTM RT-LAMP | ||||
Breast cancer | Breast cancer miRNA Assay | ||||
Hereditary Breast Cancer | DLP™Q BRCA Real Detection | ||||
Solid cancer (7 types) | DLP™Q miRNA Assay (Colon cancer, Pancreatic cancer, Stomach cancer, Lung cancer, Liver cancer, Uterine cancer, Prostate cancer) | ||||
Alzheimer Disease | DLP™Q ALZ Real Detection | ||||
Respiratory diseases | DLP™Q RV 15 Real Detection | ||||
Solid cancer (7 types) | DLP™Q methylation Assay |
Target disease | Designation | Chemisty/Size | Source technology research | Candidate material selection | Analytical performance evaluation | Clinical trial |
---|---|---|---|---|---|---|
Cervical cancer | DIG_701 | PS/15~20mer | ||||
Breast Cancer | DIG_501 | PS/15~20mer | ||||
Colon Cancer | DIG_301 | PS/15~20mer | ||||
Pancreatic Cancer | DIG_1001 | PS/15~20mer | ||||
Alzheimer Disease | DIG_1401 | PS/15~20mer | ||||
Influenza | DIG_504 | PS/15~20mer | ||||
Alzheimer Disease | DIG_1401 | PS/15~20mer |